Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Strong Year For Cephalon, But An Uncertain Future Remains

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.

You may also be interested in...

Generic Opportunities In 2012 Diluted By Shared Exclusivities

Despite the patent cliff, 2012 is one of the final years of blockbusters going generic, leaving the large generic companies to establish their place in the morphing market.

Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million

The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X

Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon

A second “complete response” letter from FDA derails development of the jet lag claim; Cephalon repeatedly has struck out in seeking a new indication to differentiate the wakefulness drug from Provigil.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts